Gefitinib (Iressa®)

Assessment Status Assessment process complete
Drug Gefitinib
Brand Iressa®
Indication For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.
Assessment Process
Full pharmacoeconomic assessment commissioned by HSE 16/06/2010
NCPE assessment completed 05/11/2020

We do not recommend the reimbursement of gefitinib for first line therapy on the High Tech Drug Scheme.  However, it may be considered for second line therapy.

Technical Summary